Amplify to Liquidate Weight Loss Drug & Treatment ETF in December

Amplify ETFs has announced plans to liquidate its Amplify Weight Loss Drug & Treatment ETF following a November 10, 2026, decision by the fund's Board of Trustees. The ETF, which provides exposure to companies involved in weight loss drugs and treatments, will stop accepting creation orders after November 26, with trading on NYSE Arca scheduled to end after the market close on December 3. Shareholders who retain their positions will have their shares automatically redeemed for cash at the fund's December 3 net asset value, with liquidation proceeds expected around December 8. Ahead of the closure, the fund may shift into cash or securities outside its normal investment strategy. Investors may face capital gains or losses upon redemption, as well as potential final distributions.